OncoCyte Corp. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
277.00
281.00
283.00
387.00
580.00
559
Gross Income
277.00
281.00
283.00
387.00
580.00
559
SG&A Expense
3,218.00
4,692.00
8,435.00
10,753.00
18,269.00
14,018
EBIT
3,495.00
4,973.00
8,718.00
11,140.00
18,849.00
14,577
Non Operating Income/Expense
-
11.00
2.00
-
309.00
91
Interest Expense
-
2.00
19.00
28.00
217.00
216
Pretax Income
3,495.00
4,986.00
8,735.00
11,168.00
19,375.00
15,754
Consolidated Net Income
3,495.00
4,986.00
8,735.00
11,168.00
19,375.00
15,754
Net Income
3,495.00
4,986.00
8,735.00
11,168.00
19,375.00
15,754
Net Income After Extraordinaries
3,495.00
4,986.00
8,735.00
11,168.00
19,375.00
15,754
Net Income Available to Common
3,495.00
4,986.00
8,735.00
11,168.00
19,375.00
15,754
EPS (Basic)
0.19
0.27
0.42
0.42
0.64
0.42
Basic Shares Outstanding
25,422.00
25,422.00
21,009.00
26,529.00
30,195.00
37,850
EPS (Diluted)
0.14
0.20
0.42
0.42
0.64
0.42
Diluted Shares Outstanding
25,422.00
25,422.00
21,009.00
26,529.00
30,195.00
37,850
EBITDA
3,218.00
4,692.00
8,435.00
10,753.00
18,269.00
14,018
About OncoCyte
View Profile
